IP Library Granted Patent US 8,143,240
Granted Patent B2
US 8,143,240 · App. 12/457,870 · Granted Mar 27, 2012

17α, 21-dihydroxypregnene esters as antiandrogenic agents

Assignee: Cosmo S.p.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,143,240
App. No.
12/457,870
Granted
Mar 27, 2012
Kind
B2
Abstract

17α,21-Dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.

Claims (15)

1. A method of treating a patient suffering from a condition selected from the group consisting of acne, seborrhea, hirsutism and alopecia, comprising administering to said patient topically or systemically an effective amount of a compound of formula (I)

wherein:

R 1 is hydrogen and R 2 is a C 3 -C 18 acyl group.

2. A method of treating a patient suffering from a condition selected from the group consisting of acne, seborrhea, hirsutism, and alopecia, said method comprising administering to said patient an effective amount of a compound of formula (II)

wherein:

R 1 and R 2 , which can be the same or different, are hydrogen or a C 3 -C 18 acyl group, with the proviso that at least one of R 1 and R 2 is different from hydrogen.

3. The method as claimed in claim 2 wherein R 1 is hydrogen and R 2 is propionyl.

4. The method as claimed in claim 2 wherein R 1 and R 2 are butanoyl.

5. A method of treating a patient suffering from a condition selected from the group consisting of acne, seborrhea, hirsutism and alopecia, comprising administering to said patient topically or systemically an effective amount of a pharmaceutical composition comprising as active ingredient a compound of formula (I)

wherein:

R 1 is hydrogen and R 2 is a C 3 -C 18 acyl group, in admixture with an acceptable carrier, wherein said active ingredient is present in an amount of 0.1 to 1.0% by weight.

6. The method as claimed in claim 2 , wherein the compound of formula (II) is administered topically or systemically.

7. A method as claimed in claim 1 wherein the compound of formula (I) is as defined in claim 1 , wherein R 1 is hydrogen and R 2 is propionate.

8. A method as claimed in claim 1 wherein the compound of formula (I) is as defined in claim 1 , wherein R 1 is hydrogen and R 2 is butyrate.

9. A method as claimed in claim 5 wherein the active ingredient is present in an amount of 0.2-0.8% by weight.

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 19, 2024
From: CASSIOPEA S.P.A.
To: CASSIOPEA S.P.A.
Reel/Frame 068998/0233 →
CHANGE OF NAME Recorded Jul 23, 2015
From: COSMO DERMATOS SRL
To: CASSIOPEA S.P.A.
Reel/Frame 036163/0294 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2014
From: COSMO S.P.A.
To: COSMO DERMATOS SRL.
Reel/Frame 031883/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2012
From: AJANI, MAURO; MORO, LUIGI
To: COSMO SPA
Reel/Frame 027714/0413 →
Priority Claims (1)
IT MI2001A1762 · Aug 10, 2001 · national
Continuity (2)
Division 10486386 · Sep 16, 2004
Related Publication 20090264396A1 · Oct 22, 2009